Publications by authors named "Kirstin Lund"
Article Synopsis
- A study tested a Bayesian dosing tool for warfarin and found that it continued to give biased maintenance dose predictions in a new group of patients.
- The research examined the effects of specific genotypes (CYP2C9 and VKORC1) on the dosing predictions and compared the original patient population used to create the dosing tool with the new group.
- Results showed that doses were overpredicted for patients needing higher doses (≥7 mg/d), with the bias unaffected by genotype or differences between the two patient groups, indicating a need for a better dosing model.
Background: Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are neoplastic disorders of hematopoietic stem cells. DNA methyltransferase inhibitors, 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine), benefit some MDS/AML patients. However, the role of DNA methyltransferase inhibitor-induced DNA hypomethylation in regulation of gene expression in AML is unclear.
View Article and Find Full Text PDFPoor warfarin control with resultant high International Normalized Ratios (INRs) and bleeding events is most common during the first months of treatment. The effects of genetic polymorphisms at the vitamin K epoxide reductase [VKORC1] and cytochrome P450 2C9 [CYP2C9] loci have been increasingly acknowledged as contributory factors of enhanced warfarin sensitivity. In our prospective, blinded study, 557 patients (49·1% male, mean age 65·4 years, range 18-91 years) commencing warfarin (target INR 2·5) were genotyped and monitored through the first 3 months of anticoagulation.
View Article and Find Full Text PDF